Proactive Investors - Run By Investors For Investors

Antibe Therapeutics hosts successful annual and special general meeting

The firm said shareholders elected six directors at its annual general meeting
pills
Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging efficacy study for the drug remains on track

Antibe Therapeutics (CVE:ATE) (OTCMKTS:ATBPF) released a shareholder update Tuesday, which highlighted its annual general and special meeting, noting all resolutions outlined in the management information circular were approved. 

The firm noted shareholders elected a number of directors: Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John Wallace and Yung Wu. 

Shareholders also approved the reappointment of Ernst & Young LLP, Chartered Accountants, as Antibe's auditor, as well as an amendment to the restricted share unit plan. 

READ: Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346

Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging, efficacy study for the drug remains on track.

The firm is developing a platform of unique drugs to prevent gastrointestinal damage and bleeding caused by using non-steroidal anti-inflammatory drugs known as NSAIDs, which are currently the primary therapy for pain relief. 

Shares of Antibe were at C$0.32 on Tuesday. 

Contact Katie Lewis at [email protected]

View full ATE profile View Profile

Antibe Therapeutics Timeline

Related Articles

A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
rasuvo
May 30 2019
The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases
parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use